Regeneron Pharmaceuticals Inc REGN

Regeneron Pharmaceuticals, Inc. es una empresa de biotecnología que descubre, inventa, desarrolla, fabrica y comercializa medicamentos para el tratamiento de enfermedades graves. La empresa comercializa medicamentos y candidatos a productos para enfermedades oculares, alérgicas e inflamatorias, cáncer, enfermedades cardiovasculares y metabólicas, dolor, enfermedades infecciosas y enfermedades raras. Los productos comercializados de la empresa incluyen EYLEA (aflibercept) Inyección, Dupixent (dupilumab) Inyección, Libtayo (cemiplimab) Inyección, Praluent (alirocumab) Inyección, Kevzara (sarilumab) Solución para Inyección Subcutánea, Inmazeb (atoltivimab, maftivimab y odesivimab-ebgn) Inyección, ARCALYST (rilonacept) Inyección para Uso Subcutáneo y ZALTRAP (ziv-aflibercept) Inyección para Infusión Intravenosa.

Con 1 acción de REGN (USD 726,52) habrías recibido USD 3,70 en dividendos en los últimos 12 meses.

• Zacks Investment Research 2 oct

  Sanofi, Regeneron Expand Immunology Alliance With New Antibodies

  Sanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030.

  

• The Motley Fool 1 oct

  Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy?

  Royalty Pharma (RPRX) offers investors diversified exposure to blockbuster drugs through a unique royalty-based investment model. With strong returns on invested capital (14.9% average ROIC), ownership in 16 blockbuster drugs, and analyst forecasts suggesting significant multiple expansion potential, the stock appears undervalued despite a 50% year-to-date surge. However, risks include share dilution and increasing competition in the pharma royalty space.

  

• Zacks Investment Research 1 oct

  Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win

  At the 2026 EASD conference in Milan, Eli Lilly and Novo Nordisk presented competing clinical data in the weight-loss drug market. Lilly's retatrutide showed 34.9% of patients lost at least 25% of body weight, while Novo countered with cardiovascular safety data for Ozempic. The GLP-1 market is expanding rapidly with over 27% of global adults eligible for these medications, attracting competition from Pfizer, Amgen, and Regeneron. Healthcare ETFs like OZEM, HRTS, and THNR offer diversified exposure to this growing sector.

  

• GlobeNewswire Inc. 30 sept

  Homozygous Familial Hypercholesterolemia (HoFH) - 7MM Market, Epidemiology, and Forecast - 2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities

  The HoFH market is expected to expand through 2036, driven by improved genetic screening, earlier diagnosis, and adoption of targeted lipid-lowering therapies. With approximately 1,840 diagnosed prevalent cases in the 7MM in 2025, the market is shifting toward long-acting, receptor-independent therapies including RNA interference agents and ANGPTL3 inhibitors. Key unmet needs include limited treatment efficacy for patients with minimal LDL receptor function, delayed diagnosis, and high treatment burden.

  

• Zacks Investment Research 29 sept

  REGN or ILMN: Which Is the Better Value Stock Right Now?

  A comparison of two Medical-Biomedical and Genetics stocks reveals that Regeneron (REGN) presents a better value opportunity than Illumina (ILMN) for value investors. REGN has a stronger Zacks Rank of #1 (Strong Buy) versus ILMN's #2 (Buy), along with significantly more attractive valuation metrics including a forward P/E of 14.16 versus ILMN's 50.77, and a PEG ratio of 1.23 versus 3.85.